About Us

Wugen Inc.

Wugen is dedicated to developing off-the-shelf cell therapies for treatment of cancer

These cell therapy drugs originate from healthy donors and are amplified in order to enhance cancer cell elimination. Our Immuno-Oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML), multiple myeloma (MM) and T-cell malignancies.

At Wugen, we are focused on off-the-shelf:

  • NK cell therapies targeting solid tumors, AML, and MM
  • CAR-T targeting T-cell malignancies
  • CAR-T targeting AML blasts while avoiding healthy stem cells

Our issued and pending patents support and protect a strong pipeline of cancer therapies offered to patients with high risk cancers.

Next in our story
Scroll to Top